Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
Yasuko Aitoku, chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan’s Access Committee, on March 18 offered proposals on how Japan should operate its soon-to-launch cost-effectiveness assessment (CEA) system, urging the government to limit the CEA application…
To read the full story
Related Article
ORGANIZATION
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…